BMD-Related Genetic Risk Scores Predict Site-Specific Fractures as Well as Trabecular and Cortical Bone Microstructure

Maria Nethander,1,2 Ulrika Pettersson-Kymmer,3 Liesbeth Vandenput,1 Mattias Lorentzon,1,4,5 Magnus Karlsson,6 Dan Mellström,1,4 and Claes Ohlsson1,7

1Centre for Bone and Arthritis Research, Department of Internal Medicine and Clinical Nutrition, Institute of Medicine, Sahlgrenska Academy, University of Gothenburg, SE-413 45 Gothenburg, Sweden; 2Bioinformatics Core Facility, Sahlgrenska Academy, University of Gothenburg, SE-405 30 Gothenburg, Sweden; 3Clinical Pharmacology, Department of Pharmacology and Clinical Neuroscience, Umea University, SE-901 87 Umea, Sweden; 4Geriatric Medicine, Institute of Medicine, Sahlgrenska Academy, University of Gothenburg, SE-431 80 Gothenburg, Sweden; 5Mary Mackillop Institute for Health Research, Australian Catholic University, Melbourne VIC 9000, Australia; 6Clinical and Molecular Osteoporosis Research Unit, Department of Orthopedics and Clinical Sciences, Lund University, Skåne University Hospital, SE-221 00 Malmö, Sweden; and 7Sahlgrenska University Hospital, Department of Drug Treatment, SE-413 45 Gothenburg, Sweden

ORCID numbers: 0000-0003-3688-906X (M. Nethander); 0000-0002-0557-9803 (U. Pettersson-Kymmer); 0000-0002-1712-6131 (L. Vandenput); 0000-0003-0749-1431 (M. Lorentzon); 0000-0003-2761-3723 (D. Mellström); 0000-0002-9633-2805 (C. Ohlsson).

Context: It is important to identify patients at highest risk of fractures.

Objective: To compare the separate and combined performances of bone-related genetic risk scores (GRSs) for prediction of forearm, hip and vertebral fractures separately, as well as of trabecular and cortical bone microstructure parameters separately.

Design, Setting, and Participants: Using 1103 single nucleotide polymorphisms (SNPs) independently associated with estimated bone mineral density of the heel (eBMD), we developed a weighted GRS for eBMD and determined its contribution to fracture prediction beyond 2 previously developed GRSs for femur neck BMD (49 SNPs) and lumbar spine BMD (48 SNPs). Associations between these GRSs and forearm (n_cases = 1020; n_controls = 2838), hip (n_cases = 1123; n_controls = 2630) and vertebral (n_cases = 288; n_controls = 1187) fractures were evaluated in 3 Swedish cohorts. Associations between the GRSs and trabecular and cortical bone microstructure parameters (n = 426) were evaluated in the MrOS Sweden cohort.

Results: We found that eBMD_GRS was the only significant independent predictor of forearm and vertebral fractures while both FN-BMD_GRS and eBMD_GRS were significant independent predictors of hip fractures. The eBMD_GRS was the major GRS contributing to prediction of trabecular bone microstructure parameters while both FN-BMD_GRS and eBMD_GRS contributed information for prediction of cortical bone microstructure parameters.

Abbreviations: AIC, Akaike information criterion; AUC, area under the receiver operating characteristic curve; BMD, bone mineral density; BUA, bone ultrasound attenuation; CT, computed tomography; DXA, dual-energy x-ray absorptiometry; eBMD, estimated bone mineral density of the calcaneus; eBMD_GRS, weighted genetic risk score for estimated bone mineral density of the calcaneus; FDR, false discovery rate; FN-BMD, femoral neck bone mineral density; FN-BMD_GRS, weighted genetic risk score for femoral neck bone mineral density; GWAS, genome-wide association study; HRpQCT, high resolution peripheral quantitative computed tomography; IBS, identical-by-state; LS-BMD, lumbar spine bone mineral density; MOS, Osteoporotic Fractures in Men; NSHDS, Northern Sweden Health and Disease Study; SNP, single nucleotide polymorphism; SOS, speed of sound; UFO, Umeå Fracture and Osteoporosis; vBMD, volumetric bone mineral density.
Osteoporosis is a disease characterized by low bone mass and micro-architectural deterioration of bone tissue, leading to increased risk of fragility fractures (1). Fracture risk is inversely associated with bone strength, which is dependent on bone mineral density (BMD) as well as bone quality parameters such as trabecular and cortical bone microstructure parameters (2, 3).

Ultrasound measures of the calcaneus (heel) predict fracture risk and this association partly remains after adjustment for hip BMD, suggesting that ultrasound captures unique bone property information of importance for fracture risk (4, 5). Detailed studies using three-dimensional high resolution peripheral quantitative computed tomography (HRpQCT) have revealed that both trabecular and cortical bone microstructure parameters also contribute to fracture prediction beyond two-dimensional dual-energy x-ray absorptionmetry (DXA)-derived BMD (6–11). Recent data indicate that the different HRpQCT measures may predict fractures in a bone site-specific manner (12).

In the clinical setting, it is important to identify the patients at highest risk of fracture, who are most likely to benefit from osteoporosis treatment (3). Today, osteoporosis diagnosis and fracture risk prediction are based on imaging (particularly DXA) in combination with assessment of clinical risk factors; the latter are often incorporated in fracture risk prediction tools. It is likely that the genetic and environmental factors that determine fracture risk differ substantially between fractures at different bone sites with different proportions of trabecular and cortical bone. However, current available fracture risk prediction tools do not include information on trabecular or cortical bone microstructure parameters and are not designed to distinguish between differences in prediction of bone site-specific fractures (13, 14). It is possible that factors regulating trabecular bone microstructure are major determinants of vertebral fracture risk, while factors determining cortical bone parameters and risk of falls are major determinants of hip fracture risk. We propose that novel separate predictors for bone site-specific fractures as well as for cortical and trabecular bone microstructure parameters may be useful for the development of personalized medicine. A certain combination of predictors might then be used to identify high risk subjects for bone site-specific fractures and also to determine whether treatments mainly targeting trabecular or cortical bone mass should be considered.

Several bone parameters including femoral neck BMD (FN-BMD) and lumbar spine BMD (LS-BMD) measured by DXA, ultrasound measures at the calcaneus and HRpQCT-derived trabecular and cortical bone parameters are highly heritable (15–20). A meta-analysis of genome-wide association studies (GWAS) has identified 63 independent single nucleotide polymorphisms (SNPs) associated with either FN-BMD or LS-BMD (21), and a recent large scale GWAS in the UK-Biobank identified as many as 1103 independent SNPs associated with estimated BMD (eBMD) from ultrasound measures at the calcaneus (22). The identified SNPs can be used for the development of genetic risk scores (GRSs) that may be used to predict bone health-related phenotypes. Unfortunately, the number of SNPs identified by informative computed tomography (CT) measurements of trabecular and cortical bone parameters separately is low and the variance explained by these SNPs of the respective bone phenotype is marginal. Therefore, no powerful meaningful GRS for separate prediction of trabecular and cortical bone parameters can be developed (23–26).

Two previous studies have used available DXA-derived SNPs for the development of different GRSs to predict risk of fractures in independent data sets (3,27), demonstrating that these GRSs were modest predictors of fractures. Importantly, these studies did not determine the bone site-specific prediction of fracture risk. GRSs based on SNPs associated with ultrasound-derived eBMD (eBMD_{GRS}) have neither been evaluated for fracture prediction in an independent data set nor for bone site-specific prediction of fracture risk (22,28).

In this study, we hypothesized that different GRSs or combination of GRSs, developed from recent well-powered GWAS on ultrasound-derived and DXA-derived relevant bone parameters, may be used for bone site-specific prediction of fracture as well as of separate

Conclusions: The eBMD_{GRS} independently predicts forearm and vertebral fractures while both FN-BMD_{GRS} and eBMD_{GRS} contribute independent information for prediction of hip fractures. We propose that eBMD_{GRS} captures unique information about trabecular bone microstructure useful for prediction of forearm and vertebral fractures. These findings may facilitate personalized medicine to predict site-specific fractures as well as cortical and trabecular bone microstructure separately. (J Clin Endocrinol Metab 105: e1344–e1357, 2020)

Key Words: bone mineral density, genetic risk scores, fractures, bone microstructure, trabecular, cortical
prediction of trabecular and cortical bone microstructure parameters. In particular, we hypothesized that the eBMD\textsubscript{GRS} developed from a high number of identified SNPs explaining a substantial part of the variance (20.3%) in eBMD at the calcaneus, may contribute information for bone site–specific fracture prediction beyond previously developed DXA-based GRSs \cite{22}. As the calcaneus is a bone with an exceptionally high trabecular bone content \cite{29}, we hypothesized that the eBMD\textsubscript{GRS} might capture unique information of trabecular bone microstructure, not identified by DXA-derived GRSs, useful for prediction of fracture risk at bone sites with a relatively high proportion of trabecular bone. The unique well-powered fracture cohorts from the Umeå Fracture and Osteoporosis (UFO) study, used in the present study for comparing bone site–specific fracture prediction of the different GRSs, did not have information on traditional clinical risk factors or FN-BMD. Therefore, the aim of the present explorative study was not to determine the clinical utility of the evaluated GRSs beyond current available fracture risk prediction tools.

**Materials and Methods**

**Study participants**

**UFO cohort.** The Umeå Fracture and Osteoporosis (UFO) study is a population-based study designed to identify the genetic and environmental determinants of osteoporotic fractures. This cohort is sampled from the Northern Sweden Health and Disease Study (NSHDS), a longitudinal, population-based cohort study from Northern Sweden, consisting of blood samples, and lifestyle and dietary data from approximately 100,000 unique individuals from the county of Västerbotten (approximately 255,000 inhabitants as of Dec 31, 2007) \cite{30,31}. The UFO-hip and UFO-forearm GWAS fracture cohorts (recruited in 2008) are subcohorts of the UFO cohort, currently including approximately 5000 fracture cases and approximately 5000 controls \cite{30}. Hip and forearm fracture cases were identified by merging the NSHDS cohort with medical records and radiographic reports. From 1993 to 2008, we identified 1086 subjects with low-trauma forearm fractures and 1086 subjects with hip fractures who were also represented with a DNA sample in the biobank. A low-trauma forearm fracture was defined as a fracture resulting from a fall from a standing position or lower. Thus, forearm fractures occurring after falls from >1 m or from traffic accidents were excluded. The UFO studies have been approved by local ethical committees and informed consent was obtained from all study participants.

The UFO-forearm fracture study is a nested case-control study in which each fracture case is compared with 1 control selected from the NSHDS cohort, matched for gender and age at recruitment, comprising a total of 2172 subjects of whom 2115 passed the quality check for genotyping. All patients in the UFO-forearm fracture study completed a survey about how the forearm fracture occurred. Only fractures caused by low energy trauma were included for forearm fractures. To refine the forearm fracture phenotype in this study, 36 subjects who had another known non-forearm fracture were excluded and 101 subjects were excluded for missing height and/or weight data, resulting in a final cohort of 1978 subjects (984 forearm cases and 994 controls). The inclusion criteria for cases in the UFO-forearm GWAS fracture cohort were an age of ≥ 30 years and having a low-trauma forearm fracture as defined by medical records and/or radiograph reports. The inclusion criteria for the forearm controls were an age of ≥ 30 years with no low-trauma fracture (until year 2008) and matching for gender and age at baseline (Table 1).

The UFO-hip fracture study is a case-cohort study in which the 1086 fracture cases are compared with a set of 934 controls, comprising a total of 2020 participants, of whom 1941 passed the quality check for genotyping. Fracture patients from the larger hospital in Umeå but not from the 2 smaller hospitals in Lycksele and Skeletté completed a survey about how the hip fracture occurred. Only fractures caused by low energy trauma were included for hip fractures for the patients in Umeå. To refine the hip fracture phenotype in this study, 19 subjects who had another known non-hip fracture were excluded and 49 subjects were excluded for missing height and/or weight data, resulting in a final cohort of 1873 participants (994 hip cases and 879 controls). The inclusion criteria for the

<table>
<thead>
<tr>
<th>Table 1. Characteristics of Study Participants</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>UFO Hip-Fracture</strong> (n = 1873)</td>
</tr>
<tr>
<td>Age (years)</td>
</tr>
<tr>
<td>BMI (kg/m(^2))</td>
</tr>
<tr>
<td>Height (cm)</td>
</tr>
<tr>
<td>Weight (kg)</td>
</tr>
<tr>
<td>Females (n, %)</td>
</tr>
<tr>
<td>Hip fracture cases (n, %)</td>
</tr>
<tr>
<td>Forearm fracture cases (n, %)</td>
</tr>
<tr>
<td>Vertebral fractures cases (n, %)</td>
</tr>
<tr>
<td>eBMD\textsubscript{GRS}</td>
</tr>
<tr>
<td>FN-BMD\textsubscript{GRS}</td>
</tr>
<tr>
<td>LS-BMD\textsubscript{GRS}</td>
</tr>
</tbody>
</table>

Values are given as mean (SD) or n (%). *Percent of patients with validated vertebral fractures was calculated based on the 1475 participants with vertebral fracture information.
cases in the UFO-hip GWAS fracture cohort were an age of ≥ 20 years and a hip fracture defined by medical records and/or radiograph reports. Subjects with a previous known low-trauma forearm fracture were excluded. The UFO-hip GWAS fracture controls were drawn from the controls of a previous GWAS study of glioma (32) (Table 1).

**MrOS Sweden**

The Osteoporotic Fractures in Men (MrOS) study is a multicenter, prospective study including older men in Sweden, Hong Kong, and the United States. The MrOS Sweden cohort consists of 3 sub-cohorts from 3 Swedish cities (n = 1005 in Malmö, n = 1010 in Gothenburg, and n = 999 in Uppsala). Study participants (men aged 69 to 81 years) were randomly selected through national population registers, contacted, and asked to participate. A total of 45% of the subjects who were contacted participated in the study. To be eligible for the study, the participants had to be able to walk without assistance, provide self-reported data, and sign an informed consent (33). In this study, we included 1880 participants (953 from Gothenburg and 927 participants from Malmö) with available genetic data that passed the quality check for genotyping (Table 1). Participants in the MrOS Sweden cohort were followed for up to 10 years after the baseline examination. Fracture evaluation was done by searching digital x-ray archives and matching them with MrOS Sweden participants using unique personal identification number, which all Swedish citizens have. All reported fractures after baseline were confirmed by physician review of radiology report. Fractures with ICD10 code S72.0, S72.1, or S72.2 were classified as hip fractures while ICD10 code S52.5 and S52.6 were classified as forearm fractures (Table 1). Vertebral fractures were identified using thoracic spine x-ray at up to 3 occasions (at baseline, after 3 years and after 5 years). The radiographs were evaluated for radiographic vertebral fractures by an expert radiologist using a modified semiquantitative method developed by Genant and colleagues (34, 35). Individuals with a radiographic vertebral fracture at any of the occasions were classified as fracture cases while individuals with at least 1 x-ray and no vertebral fracture identified were classified as non-cases. Individuals without any thoracic spine x-ray were excluded from the analyses of radiographic vertebral fractures (Table 1). No information about the underlying cause of fracture is available for MrOS Sweden. The study was approved by the ethics committees at the Universities of Gothenburg, Lund, and Uppsala and informed consent was obtained from all study participants.

**Genotyping**

**UFO cohort**

**UFO-forearm fracture cohort.** Genotyping of the forearm fracture cohort was performed using Illumina Omni express arrays. Genotypes were called using the BeadStudio calling algorithm. The sample quality control exclusion criteria were a sample call rate < 97.5%, gender discrepancy with genetic data from X-linked markers, excess autosomal heterozygosity > 0.33 (false discovery rate [FDR] < 0.1%), duplicates and/or first-degree relatives identified using identical-by-state (IBS) probabilities (>97%), ethnic outliers (3 standard deviations [SD] away from the population mean) using multidimensional scaling analysis with 4 principal components. Genotypes from 2115 individuals (1055 controls and 1060 cases) passed the sample quality control.

**UFO hip fracture cohort.** Genotyping of the hip fracture cohort was performed using Illumina HumanHap660 arrays. Genotypes were called using the BeadStudio calling algorithm. The sample quality control exclusion criteria were a sample call rate < 97.5%, gender discrepancy with genetic data from X-linked markers, excess autosomal heterozygosity > 0.33 (FDR < 0.1%), duplicates and/or first-degree relatives identified using IBS probabilities (>97%), ethnic outliers (3 SD away from the population mean) using multidimensional scaling analysis with 4 principal components. Genotypes from 1941 individuals (891 controls and 1050 cases) passed the sample quality control.

**MrOS Sweden**

**Gothenburg part.** Genotyping, imputation, and quality controls were performed using the Illumina HumanOmni1_Qaud_v1-0 B array. Genotypes were called using the Illumina’s BeadStudio calling algorithm. The sample quality control exclusion criteria were a sample call rate < 97%, excessive autosomal heterozygosity, first- and second-degree relatives, genotypic sex mismatch using X and Y chromosome probe intensities, and gross chromosome abnormalities. Genotyped SNPs with GenTrain scores < 0.6, cluster separation scores < 0.4, call rates < 97%, or minor allele frequency < 0.01 were excluded. Also, autosomal SNPs with Hardy-Weinberg Equilibrium P value < 10^{-4} were excluded and genotype clusters for SNPs on chrX, chrY, chrXY, and chrM were reviewed manually. 714 543 autosomal SNPs passed quality control. Genotypes from 953 individuals passed the sample quality control.

**Malmö part.** Genotyping and quality controls were performed using the HumanOmniExpress-12v1_B build 36. The sample quality control exclusion criteria were sample call rate < 97.5%, missing data, excessive autosomal heterozygosity, familiar relationship (1 sample excluded), genotypic sex mismatch, non-Caucasian ethnicity, and gross chromosome abnormalities. SNPs with
call rates < 95% were excluded. 725,409 autosomal
SNPs passed quality control. Genotypes from 927 indi-
viduals passed the sample quality control.

**Imputation**

For all cohorts, genotypes were imputed to the
Haplotype Reference Consortium release 1.1 refer-
cence panel (36) yielding dosages for all SNPs, that
is, continuous estimates of the number of risk al-
leles. The imputation was done separately for each
cohort. Both pre-phasing and imputation were done
using Sanger Imputation Service. SNPs with no vari-
ance or low imputation quality (< 0.3) were excluded.
The HRC.r1 release consists of 64,940 haplotypes
and a total of 40,405,505 variants of predominantly
European ancestry.

**Three different genetic risk scores**

We defined 3 GRSs (FN-BMD GRS, LS-BMD GRS,
and eBMD GRS) based on previously identified SNPs
associated with the corresponding BMD measure
in large-scale GWAS (21, 22). A total of 1103 inde-
pendent SNPs have been identified to associate with
eBMD (22). In MrOS Sweden and the UFO cohorts,
1083 and 1085 SNPs, respectively, out of the 1103
SNPs had high-quality imputed dosage information
available and were used for the calculation of the
eBMD GRS. The GWAS results, including the effect sizes
for the 1103 eBMD SNPs used in this study, are pub-
licly available from Supplementary Table 2 in the ori-
ginal publication (22). Out of the 63 independent SNPs
identified in the GWAS on FN-BMD and LS-BMD
(21), 49 SNPs were associated with FN-BMD (P < 5 \times 10^{-8}) and included in the FN-BMD GRS while 48 of the
63 SNPs were associated with LS-BMD (P value < 5 \times 10^{-8}) and included in the LS-BMD GRS. All these 63
SNPs were imputed with high quality in UFO while
1 SNP had low imputation quality in MrOS Sweden and
was excluded. The GWAS results, including the effect sizes for the 49 SNPs associated with FN-BMD and the 48 SNPs associated with LS-BMD are publicly available from Supplementary Tables 4A and 4B in the original publication (21). There is an overlap between the SNPs in the eBMD GRS and the 2 DXA-derived GRSs. A total of 27 of the SNPs in FN-BMD GRS and 28 of the SNPs in LS-BMD GRS are represented in the
eBMD GRS by either the same SNP or a SNP with an \(R^2 \geq 0.8\). For each individual, the GRSs were defined as the weighted sum of SNP dosages, where SNP ef-
fects from the corresponding BMD GWAS were used as weights. The GRSs were standardized to have a
mean of zero and SD of 1.

**Bone measures**

**Estimated BMD (eBMD) using ultrasound.** Speed of
sound (SOS) and bone ultrasound attenuation (BUA)
were measured by quantitative ultrasound (Hologic
SaHara, Waltham, MA) at the left calcaneus in MrOS
Sweden participants (37). The eBMD was then calcu-
lated as a linear combination of SOS and BUA using
the following algorithm eBMD = 0.0025926 \times (BUA + SOS) – 3.687 (38). Thus, eBMD is an indirectly
measured BMD (Table 2). The eBMD is not used for
osteooporosis diagnosis or fracture prediction in the
clinical context, but some studies have shown that
not only DXA-derived BMD but also ultrasound-
derived eBMD is strongly associated with fracture risk
(39, 40).

**Areal BMDs using DXA.** Areal BMDs (g/cm²) of the
femoral neck (FN-BMD) and lumbar spine (LS-BMD; L1–L4) were assessed using the Lunar Prodigy DXA
(GE Lunar Corp., Madison, WI) for the subjects in-
vested in MrOS Sweden/Malmö, or the Hologic
DXA Hologic QDR 4500/A-Delphi (Hologic,
Whaltman, MA) for subjects investigated in MrOS
Sweden/Gothenburg. The coefficient of variations for
the areal BMD measurements ranged from 0.5% to
3%, depending on application. To be able to use DXA
measurements performed with equipment from the 2
different manufacturers, standardized BMD was cal-
culated for these bone sites as previously described
(33, 41–43) (Table 2).

<table>
<thead>
<tr>
<th>Table 2. Bone Parameters in MrOS Sweden</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Ultrasound (n = 1880)</strong></td>
</tr>
<tr>
<td>Estimated BMD of Calcaneus (g/cm²)</td>
</tr>
<tr>
<td><strong>DXA (n = 1880)</strong></td>
</tr>
<tr>
<td>Femur Neck BMD (g/cm²)</td>
</tr>
<tr>
<td>Lumbar Spine BMD (g/cm²)</td>
</tr>
<tr>
<td><strong>HR pQCT of Distal Radius (n = 426)</strong></td>
</tr>
<tr>
<td>Failure Load (N)</td>
</tr>
<tr>
<td><strong>Trabecular parameters</strong></td>
</tr>
<tr>
<td>Trabecular vBMD (mg/cm³)</td>
</tr>
<tr>
<td>Trabecular Number (1/mm)</td>
</tr>
<tr>
<td>Trabecular Thickness (µm)</td>
</tr>
<tr>
<td><strong>Cortical parameters</strong></td>
</tr>
<tr>
<td>Cortical Area (mm²)</td>
</tr>
<tr>
<td>Cortical vBMD (mg/cm³)</td>
</tr>
<tr>
<td>Cortical Porosity (%)</td>
</tr>
</tbody>
</table>

Values are given as mean (SD).

Abbreviations: estimated BMD, estimated bone mineral density ana-
lysed by ultrasound; femur neck BMD, femoral neck bone mineral
density analysed by dual energy absorptiometry (DXA); HRpQCT, high
resolution peripheral quantitative computed tomography; lum-
bar spine BMD, lumbar spine bone mineral density analysed by DXA;
vBMD, volumetric bone mineral density.
High resolution peripheral quantitative computed tomography (HRpQCT). Volumetric bone density (vBMD) and bone microarchitecture were assessed at the ultradistal radius with XtremeCT scanners (Scanco Medical, Switzerland), which were used by operators trained by the manufacturer (11). Scans were acquired with a nominal isotropic voxel size of 82 μm³. Scanning was done on the nondominant forearm. If a participant reported previous extremity fracture or had metal in the scan region, the contralateral extremity was examined. Anteroposterior scout views were used to place a reference line on the distal radial joint surface (44). The radial scan region was 9 mm in length (110 slices) and offset proximally to the reference line by 9.5 mm. Scanning of a quality control phantom (110 slices) and offset proximally to the reference line face (44). The radial scan region was 9 mm in length to place a reference line on the distal radial joint surface. The radial scan region was 9 mm in length to place a reference line on the distal radial joint surface.

Statistical analyses

Associations between the 3 GRSs and risk of forearm, hip, and vertebral fractures were first evaluated in separate logistic regression models, adjusted for age, sex, height, weight, and MrOS site. Differences between bone measure associations for the separate GRSs were tested for significance using a z-test. Next, independent association between the 3 GRSs and different bone parameters in MrOS Sweden were evaluated using stepwise selection in combined logistic regression models, adjusted for age, sex, height, weight, and MrOS site. All analyses were performed using R version 3.4.2. Area under the receiver operating characteristic curve (AUC) and corresponding confidence intervals were calculated using the roc.test function in the pROC R-package (47).

Results

The ultrasound-based genetic risk score eBMDGRS displays modest correlations with the DXA-based genetic risk scores FN-BMDGRS and LS-BMDGRS

The means and SDs of the 3 bone-related GRSs, including the heel ultrasound-based eBMDGRS and the DXA-based FN-BMDGRS and LS-BMDGRS, were similar in the 3 evaluated Swedish cohorts, UFO hip fracture, UFO forearm fracture, and MrOS Sweden (Table 1). To determine if these 3 GRSs might have the potential to contribute independent information for prediction of bone health–related parameters, we first evaluated their intercorrelations in the 3 clinical cohorts used in the present study (Table 3). The FN-BMDGRS explained as much as 53.5% to 55% of the variance of the other DXA-based genetic risk score, LS-BMDGRS in the 3 cohorts. In contrast, the variances in the 2 DXA-based risk scores explained by the newly-developed ultrasound-based eBMDGRS were rather modest: FN-BMDGRS (9.2% to 13.5%) and LS-BMDGRS (12.6% to 14.8%) (Table 3). Thus, the new different bone parameters in MrOS Sweden were first evaluated in separate linear regression models, adjusted for age, sex, height, weight, and MrOS site. Differences between bone measure associations for the separate GRSs were tested for significance using a z-test. Next, independent association between the 3 GRSs and different bone parameters in MrOS Sweden were evaluated using stepwise selection in combined linear regression models, adjusted for age, sex, height, weight, and MrOS site. All analyses were performed using R version 3.4.2. Area under the receiver operating characteristic curve (AUC) and corresponding confidence intervals were calculated using the roc.test function in the pROC R-package (47).

Table 3. Cross Tab of Variance Explained (R²) for the 3 Genetic Risk Scores

<table>
<thead>
<tr>
<th></th>
<th>FN-BMDGRS</th>
<th>LS-BMDGRS</th>
</tr>
</thead>
<tbody>
<tr>
<td>UFO Hip-Fracture</td>
<td></td>
<td></td>
</tr>
<tr>
<td>eBMDGRS</td>
<td>12.2%</td>
<td>13.3%</td>
</tr>
<tr>
<td>FN-BMDGRS</td>
<td>53.5%</td>
<td>53.5%</td>
</tr>
<tr>
<td>UFO Forearm-Fracture</td>
<td></td>
<td></td>
</tr>
<tr>
<td>eBMDGRS</td>
<td>13.5%</td>
<td>14.8%</td>
</tr>
<tr>
<td>FN-BMDGRS</td>
<td>54.8%</td>
<td>54.8%</td>
</tr>
<tr>
<td>MrOS-Sweden</td>
<td></td>
<td></td>
</tr>
<tr>
<td>eBMDGRS</td>
<td>9.2%</td>
<td>12.6%</td>
</tr>
<tr>
<td>FN-BMDGRS</td>
<td>55.0%</td>
<td>55.0%</td>
</tr>
</tbody>
</table>

Abbreviations: eBMDGRS, genetic risk score for estimated bone mineral density of the heel; FN-BMDGRS, genetic risk score for bone mineral density in femur neck; LS-BMDGRS, genetic risk score for bone mineral density in lumbar spine.
eBMD\textsubscript{GRS} might contribute substantial independent information, beyond the 2 previously evaluated DXA-based GRSs, for prediction of different bone-related parameters. We next confirmed in the MrOS Sweden cohort that the different evaluated GRSs were associated with the underlying bone phenotype used for the development of the respective GRS (with a high GRS indicating a low value of the bone parameter). As expected, the eBMD\textsubscript{GRS} was significantly inversely associated with eBMD (variance explained $R^2 = 17.0\%$; $P = 8.5 \times 10^{-68}$), the FN-BMD\textsubscript{GRS} was significantly inversely associated with FN-BMD ($R^2 = 3.9\%$; $P = 5.0 \times 10^{-21}$) and the LS-BMD\textsubscript{GRS} was significantly inversely associated with LS-BMD ($R^2 = 4.6\%$; $P = 1.2 \times 10^{-21}$) (Table 4).

The eBMD\textsubscript{GRS} is an independent predictor of vertebral and forearm fractures, while both the FN-BMD\textsubscript{GRS} and the eBMD\textsubscript{GRS} contribute to hip fracture prediction

We next compared the separate and combined performances of the 3 bone-related GRSs for prediction of vertebral fractures, forearm, and hip fractures. Associations between the 3 GRSs and risk of forearm, hip, and vertebral fractures were first evaluated in separate logistic regression models. All 3 GRSs were significantly directly associated with fracture risk at all 3 bone sites (Fig 1). For forearm fractures and vertebral fractures, the effect sizes, expressed as odds ratio (OR) per SD increase in GRS, were rather similar for the FN-BMD\textsubscript{GRS} and the eBMD\textsubscript{GRS} (Fig 1). AUCs for fracture discrimination for the GRSs in each of the included cohorts are given in Table 5. In general, these AUC data support the notion that the eBMD\textsubscript{GRS} is the most informative GRS for prediction of wrist and vertebral fractures, while the AUCs of the eBMD\textsubscript{GRS} and the FN-BMD\textsubscript{GRS} are of similar magnitude for hip fracture discrimination. As the GRSs were correlated with each other, we next evaluated the independent associations between the 3 GRSs and risk of fractures, using stepwise selection in combined logistic regression models (Fig 2). In these analyses, we observed that the eBMD\textsubscript{GRS} was the only independent predictor of forearm (OR [per SD increase] 1.46; 95% CI, 1.33-1.60) and vertebral fractures (OR 1.32; 95% CI, 1.16-1.51). In contrast, both the FN-BMD\textsubscript{GRS} (OR

| Table 4. Association Between 3 Genetic Risk Scores (GRSs) and Different Bone Parameters in MrOS Sweden, Evaluated in Separate Linear Regression Models |
|---------------------------------|-----------------|-----------------|-----------------|-----------------|-----------------|
|                                | eBMD\textsubscript{GRS} | FN-BMD\textsubscript{GRS} | LS-BMD\textsubscript{GRS} |
|                                | N | Beta | SE | $P$ | $R^2$ | Beta | SE | $P$ | $R^2$ | Beta | SE | $P$ | $R^2$ |
| Ultrasound                      |   |      |    |    |      |      |    |    |      |      |      |    |    |      |
| Calcaneus eBMD                  | 1567 | -0.41 | 0.02 | 8.5E-68 | 17.0% | -0.15 | 0.02 | 1.0E-09 | 2.3% | * | -0.16 | 0.02 | 1.0E-10 | 2.5% | * |
| DXA                            |   |      |    |    |      |      |    |    |      |      |      |    |    |      |
| FN-BMD                         | 1861 | -0.21 | 0.02 | 1.0E-24 | 4.6% | -0.20 | 0.02 | 5.0E-21 | 3.9% | * | -0.15 | 0.02 | 3.1E-12 | 2.2% | * |
| LS-BMD                         | 1865 | -0.23 | 0.02 | 3.1E-27 | 5.4% | -0.17 | 0.02 | 2.5E-16 | 3.1% | -0.21 | 0.02 | 1.2E-23 | 4.6% |    |
| HRpQCT of Distal Radius        |   |      |    |    |      |      |    |    |      |      |      |    |    |      |
| Failure Load                    | 354 | -0.38 | 0.05 | 7.0E-14 | 12.6% | -0.24 | 0.05 | 1.4E-06 | 5.5% | * | -0.22 | 0.05 | 3.1E-05 | 4.1% | * |
| Trabecular parameters           |   |      |    |    |      |      |    |    |      |      |      |    |    |      |
| vBMD                           | 403 | -0.39 | 0.05 | 4.0E-15 | 13.8% | -0.24 | 0.05 | 1.2E-06 | 5.5% | * | -0.26 | 0.05 | 9.0E-07 | 5.6% |    |
| Trabecular Number               | 357 | -0.33 | 0.05 | 1.2E-09 | 9.2% | -0.20 | 0.05 | 9.2E-05 | 3.9% | -0.24 | 0.05 | 9.2E-06 | 5.0% |    |
| Trabecular Thickness            | 357 | -0.31 | 0.05 | 9.7E-09 | 8.2% | -0.15 | 0.05 | 4.3E-03 | 2.1% | * | -0.14 | 0.05 | 1.2E-02 | 1.6% | * |
| Cortical parameters             |   |      |    |    |      |      |    |    |      |      |      |    |    |      |
| Area                            | 426 | -0.24 | 0.05 | 3.8E-07 | 5.3% | -0.22 | 0.05 | 1.6E-06 | 4.8% | -0.23 | 0.05 | 2.2E-06 | 4.6% |    |
| vBMD                            | 397 | -0.20 | 0.05 | 3.9E-05 | 3.8% | -0.22 | 0.05 | 7.4E-06 | 4.5% | -0.20 | 0.05 | 1.3E-04 | 3.3% |    |
| Porosity                        | 352 | 0.04  | 0.06 | 4.7E-01 | 0.1% | 0.05  | 0.05 | 3.2E-01 | 0.3% | 0.05  | 0.06 | 4.1E-01 | 0.2% |    |

The models for ultrasound and dual energy absorptiometry (DXA) parameters, available both in the Gothenburg and the Malmö cohort of MrOS Sweden, are adjusted for age, height, weight, and MrOS site. The models for high resolution peripheral quantitative computed tomography (HRpQCT)-derived parameters in the distal radius, available only in the Gothenburg part of MrOS Sweden, are adjusted for age, height, and weight. Betas are expressed as SD change in bone parameter per SD increase in GRS.

* $P < 0.05$ vs eBMD\textsubscript{GRS}
We next performed an explorative subanalysis dividing up both the eBMDGRS and the FN-BMDGRS into 1 GRS that included only the common SNPs (27 SNPs) and the eBMDGRS (OR 1.21; 95% CI, 1.11-1.33) contributed independent information for prediction of hip fractures.
between the \( \text{eBMD}_{\text{GRS}} \) and \( \text{FN-BMD}_{\text{GRS}} \) and 1 GRS containing only the SNPs specific for either the \( \text{FN-BMD}_{\text{GRS}} \) (22 SNPs) or the \( \text{eBMD}_{\text{GRS}} \) (1076 SNPs). This results in 6 different GRSs (\( \text{eBMD}_{\text{GRS}}, \text{CommonSNP-} \text{eBMD}_{\text{GRS}}, \text{SpecificSNP-} \text{eBMD}_{\text{GRS}}, \text{FN-BMD}_{\text{GRS}}, \text{CommonSNP-FNBM}_{\text{DGRS}}, \text{SpecificSNP-FNBM}_{\text{DGRS}} \)) (Table 6) for comparison of their associations with fracture risk at different bone sites. The \( \text{CommonSNP-} \text{eBMD}_{\text{GRS}} \) and the \( \text{CommonSNP-FNBM}_{\text{DGRS}} \) both including the same common 27 SNPs, displayed very similar patterns of association with fracture risk at all 3 bone sites (Table 6) and these associations were also very similar to the associations for the \( \text{FN-BMD}_{\text{GRS}} \) for fractures at all 3 bone sites. In contrast, the \( \text{eBMD}_{\text{GRS}} \) displayed stronger associations with forearm and vertebral fractures, but not with hip fractures, compared with the corresponding associations for the 2 Common SNP GRSs. Interestingly, the \( \text{SpecificSNP-} \text{eBMD}_{\text{GRS}} \) demonstrated very similar fracture prediction as the \( \text{eBMD}_{\text{GRS}} \) for fractures at all 3 bone sites while the \( \text{SpecificSNP-FNBM}_{\text{DGRS}} \) was only associated with risk of hip fractures. These exploratory subanalyses support the notion that a substantial part of the better performance of the \( \text{eBMD}_{\text{GRS}} \) compared with the \( \text{FN-BMD}_{\text{GRS}} \) is dependent on the larger number of SNPs and variance explained by the \( \text{eBMD}_{\text{GRS}} \). Yet, the specific \( \text{eBMD} \) SNPs seem to add unique information not captured by the \( \text{FN-BMD}_{\text{GRS}} \) for prediction of forearm and vertebral fractures.

The \( \text{eBMD}_{\text{GRS}} \) is the major predictor of trabecular bone microstructure parameters, while both the \( \text{FN-BMD}_{\text{GRS}} \) and the \( \text{eBMD}_{\text{GRS}} \) contribute independent information for prediction of cortical bone area and cortical density

**eBMD and DXA-based BMD.** We first compared the associations between the 3 GRSs and the different underlying ultrasound and DXA-based bone parameters in MrOS Sweden, evaluated in separate models. We observed that for eBMD, the \( \text{eBMD}_{\text{GRS}} \) explained substantially more of the variance than what the 2 DXA-based GRSs did (Table 4). In contrast, the \( \text{FN-BMD}_{\text{GRS}} \) explained the variance of \( \text{FN-BMD} \) similarly well as the \( \text{eBMD}_{\text{GRS}} \) did and the \( \text{LS-BMD}_{\text{GRS}} \) explained the variance of \( \text{LS-BMD} \) similarly well as the \( \text{eBMD}_{\text{GRS}} \) did. When evaluated using stepwise selection in combined linear regression models, \( \text{eBMD}_{\text{GRS}} \) was the only independent predictor of trabecular thickness (\( \textit{R}^2 = 8.2\% \)) and the major predictor of trabecular \( \text{vBMD} \) (\( \textit{R}^2 = 13.8\% \)), trabecular number (\( \textit{R}^2 = 9.2\% \)), and failure load (\( \textit{R}^2 = 12.6\% \)) (Table 7 and Fig 3). In contrast, both the \( \text{FN-BMD}_{\text{GRS}} \) and the \( \text{eBMD}_{\text{GRS}} \) contributed independently and approximately equally to the prediction of the cortical bone parameters cortical bone area and cortical \( \text{vBMD} \) (Table 7).

**Discussion**

The differences in genetic contribution to bone site-specific fracture risk and to trabecular versus cortical bone microstructure parameters are poorly investigated. In this study, we hypothesized that different GRSs or combinations of GRSs, developed from recent well-powered GWAS on ultrasound-derived and DXA-derived relevant bone parameters, may be used for the separate prediction of fractures at different bone sites, including forearm, vertebral, and hip fractures, as well as for separate prediction of trabecular and cortical bone microstructure parameters. We demonstrate that the ultrasound-based calcaneus \( \text{eBMD}_{\text{GRS}} \) captures unique information of trabecular bone microstructure parameters as well as of risk of vertebral and forearm fractures, while both the DXA-based \( \text{FN-BMD} \) and the
eBMDGRS capture unique information of cortical bone mass and hip fracture risk (Fig 4).

Two previous studies have shown that fracture risk prediction is modest when only using available DXA-derived GRSs (3, 27). The bone site-specific prediction of fracture risk was, however, not evaluated in these studies. In addition, no previous study has evaluated the impact of any bone-related GRS for cortical and trabecular bone microstructure parameters. In the present study we observed that the ultrasound-based eBMDGRS displayed modest correlations with the 2 DXA-based GRSs, demonstrating that the eBMDGRS might contribute with independent information beyond the information from DXA-derived GRSs for prediction of bone health–related parameters. Besides contributing unique bone property information not captured by the DXA-derived GRSs, the eBMDGRS explained approximately 5 times more of the variance of the underlying bone phenotype than the 2 evaluated DXA-based GRSs. The latter was most likely the result of the exceptional large UK-Biobank cohort used for the development of the eBMDGRS. This is most likely the reason why the eBMDGRS in general was a stronger predictor of fracture risk and bone microstructure parameters than the 2 evaluated DXA-based GRSs. However, importantly both for bone site-specific fracture prediction and for association with cortical versus trabecular bone microstructure parameters, there were clear differences in the patterns of the relative importance of the different GRSs. The eBMDGRS but not FN-BMDGRS independently predicted trabecular bone thickness as well as vertebral and forearm fractures. In contrast, both FN-BMDGRS and eBMDGRS independently predicted cortical bone mass parameters (cortical area and cortical thickness) and hip fractures (Fig 4). We propose that eBMDGRS captures unique information on trabecular bone microstructure useful for prediction of forearm and vertebral fractures. The strong prediction of trabecular bone parameters by eBMDGRS is most likely related to the exceptional high trabecular bone content in the calcaneus (90%) where ultrasound eBMD is measured (29). In contrast, both FN-BMDGRS and eBMDGRS capture unique information on cortical bone mass useful for prediction of hip fractures (Fig 4).

There are some clear advantages to using GRS for the prediction of different health outcomes. First, GRSs do not change over the lifetime, enabling both early identification of individuals at high risk to be considered for primary prevention strategies and for later risk assessment in patients considered for secondary prevention strategies. In addition, genome-wide array genotyping has a relatively low one-time cost and can be used to
calculate GRs not only for fracture risk prediction but also for prediction of several other complex diseases (48–50).

The main strength with the present study is the large number of x-ray–verified forearm, hip, and vertebral fractures, enabling separate fracture prediction

### Table 7. Association Between 3 Genetic Risk Scores (GRSs) and Different Bone Parameters in MrOS Sweden, Evaluated Using Stepwise Selection in Combined Linear Regression Models

<table>
<thead>
<tr>
<th>Parameter</th>
<th>eBMD&lt;sub&gt;GRS&lt;/sub&gt;</th>
<th>FN-BMD&lt;sub&gt;GRS&lt;/sub&gt;</th>
<th>LS-BMD&lt;sub&gt;GRS&lt;/sub&gt;</th>
</tr>
</thead>
<tbody>
<tr>
<td>N</td>
<td>Beta</td>
<td>SE</td>
<td>P</td>
</tr>
<tr>
<td>Ultrasound Calcaneus</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>eBMD</td>
<td>1567</td>
<td>−0.41</td>
<td>0.02</td>
</tr>
<tr>
<td>DXA Failure Load</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>FN-BMD</td>
<td>1861</td>
<td>−0.17</td>
<td>0.02</td>
</tr>
<tr>
<td>LS-BMD</td>
<td>1865</td>
<td>−0.17</td>
<td>0.02</td>
</tr>
<tr>
<td>HRpQCT of Distal Radius</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Trabecular parameters</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>vBMD</td>
<td>403</td>
<td>−0.35</td>
<td>0.05</td>
</tr>
<tr>
<td>Trabecular Number</td>
<td>357</td>
<td>−0.29</td>
<td>0.05</td>
</tr>
<tr>
<td>Trabecular Thickness</td>
<td>357</td>
<td>−0.31</td>
<td>0.05</td>
</tr>
<tr>
<td>Cortical parameters</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Area</td>
<td>426</td>
<td>−0.19</td>
<td>0.05</td>
</tr>
<tr>
<td>vBMD</td>
<td>397</td>
<td>−0.16</td>
<td>0.05</td>
</tr>
</tbody>
</table>

The models for ultrasound and dual energy absorptiometry (DXA) parameters, available both in the Gothenburg and the Malmö cohort of MrOS Sweden, are adjusted for age, height, weight, and MrOS site. The models for high resolution peripheral quantitative computed tomography (HRpQCT)-derived parameters in the distal radius, available only in the Gothenburg part of MrOS Sweden, are adjusted for age, height, and weight. Betas are expressed as SD change in bone parameter per SD increase in GRS of significant independent associations.

Abbreviations: eBMD, estimated bone mineral density analysed by ultrasound; FN-BMD, femoral neck bone mineral density analysed by DXA; LS-BMD, lumbar spine bone mineral density analysed by DXA; vBMD, volumetric bone mineral density.

**Figure 3.** The variance explained ($R^2$) of different bone parameters in MrOS Sweden by eBMD<sub>GRS</sub> and FN-BMD<sub>GRS</sub> evaluated using stepwise selection in combined linear regression analyses. Black bars = variance explained independently by eBMD<sub>GRS</sub>. White bar = variance explained independently by FN-BMD<sub>GRS</sub>. Grey bar = variance explained shared by eBMD<sub>GRS</sub> and FN-BMD<sub>GRS</sub>. Trabecular thickness, cortical bone area and cortical volumetric BMD (cortical vBMD) were analysed by high resolution peripheral quantitative computed tomography. Abbreviations: eBMD, estimated bone mineral density analysed by ultrasound; FN-BMD, femoral neck bone mineral density analysed by dual-energy absorptiometry; GRS, genetic risk score.

**Figure 4.** Summary of the separate and combined prediction of fracture types and trabecular and cortical bone microstructure by eBMD<sub>GRS</sub> and FN-BMD<sub>GRS</sub> eBMD<sub>GRS</sub> but not FN-BMD<sub>GRS</sub> independently predicted trabecular bone thickness as well as vertebral and forearm fractures. In contrast, both FN-BMD<sub>GRS</sub> and eBMD<sub>GRS</sub> independently predicted cortical bone mass parameters (cortical area and cortical thickness) and hip fractures. We propose that eBMD<sub>GRS</sub> captures unique information of trabecular bone microstructure useful for the prediction of forearm and vertebral fractures. In contrast, both FN-BMD<sub>GRS</sub> and eBMD<sub>GRS</sub> capture unique information of cortical bone mass useful for the prediction of hip fractures. Abbreviations: eBMD, estimated bone mineral density analysed by ultrasound; FN-BMD, femoral neck bone mineral density analysed by dual-energy absorptiometry.
by bone site. In addition, detailed HRpQCT analyses at the distal radius were available in a subset of MrOS Sweden, enabling us to evaluate the combined performances of the GRSs for trabecular and cortical bone microstructure parameters separately at the bone site for forearm fractures. Although we aimed to determine the predictive value of the GRSs for the separate prediction of fractures at different bone sites, as well as for trabecular and cortical bone microstructure, a limitation is that information on clinical risk factors and FN-BMD were not available in the 2 large fracture cohorts used in the present study. Further studies in large cohort with a high fracture prevalence and information on clinical risk factors and available FN-BMD are warranted to determine if the herein-identified combinations of GRSs predict bone site-specific fracture risk beyond clinical risk factors and FN-BMD. Nevertheless, current fracture models in clinical use are not designed to discriminate between risk for fractures at different bone sites (13, 14). It is a limitation with the present study that we only used stepwise regression and not more modern methods such as LASSO or Bayesian Model Averaging. Another limitation with the present study is that only individuals of white ethnic background were included, and because the genetic background varies in different populations, we cannot generalize our findings to other race/ethnic populations.

In conclusion, the eBMDGRS is the only independent GRS for prediction of forearm and vertebral fractures while both FN-BMDGRS and eBMDGRS contribute independent information for prediction of hip fractures. We propose that eBMDGRS captures unique information of trabecular bone microstructure useful for the prediction of forearm and vertebral fractures. The findings in the present study may facilitate personalized medicine to predict different fracture types as well as cortical and trabecular bone microstructure parameters separately. Personalized medicine has the potential to customize therapy with the best response and highest safety margin to ensure better patient care, by enabling each patient to receive earlier diagnoses, risk assessments, and optimal treatments.

Acknowledgments

UFO cohort

The UFO cohort is funded by the Swedish Research Council, the Swedish Foundation for Strategic Research, by grants from the Swedish state under the agreement between the Swedish government and the county councils, the ALF-agreement the Swedish Foundation for Strategic Research, by grants from the Swedish state under the agreement between the Swedish government and the county councils, the ALF-agreement the Swedish Foundation for Strategic Research, and the Novo Nordisk Foundation, and the European Commission grant HEALTH-F2-2008-201865-GEFOS, BBMRIlse, the Swedish Society of Medicine, the Kempe-Foundation (JCK-1021), the Medical Faculty of Umeå University, the county council of Västerbotten (Spjutspetsanslag VLL:159:33–2007). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

MrOS Sweden cohort

MrOS in Sweden is supported by the Swedish Research Council, the Swedish Foundation for Strategic Research, the ALF/LUA research grant in Gothenburg, the Lundberg Foundation, the Knut and Alice Wallenberg Foundation, the Torsten Söderberg Foundation, and the Novo Nordisk Foundation.

Financial Support: This work was supported by the Swedish Research Council, the Swedish Foundation for Strategic Research, by grants from the Swedish state under the agreement between the Swedish government and the county councils, the ALF research grants in Gothenburg and Västerbotten, the Lundberg Foundation, Knut and Alice Wallenberg Foundation, the Torsten and Ragnar Söderberg’s Foundation, the Novo Nordisk Foundation, the European Commission grant, BBMRIlse, the Swedish Society of Medicine, the Kempe-Foundation, the Medical Faculty of Umeå University and the county council of Västerbotten Foundation.

Additional Information

Correspondence and Reprint Requests: Professor Claes Ohlsson MD, PhD, Centre for Bone and Arthritis Research, Department of Internal Medicine and Clinical Nutrition, Institute of Medicine, Sahlgrenska Academy, University of Gothenburg, Vita Stråket 11, SE-41345 Gothenburg, Sweden. E-mail: claes.ohlsson@medic.gu.se

Disclosure Summary: The authors have nothing to disclose.

References


